esophageal cancer
Conditions
Interventions
Weekly paclitaxel for docetaxel-resistant case. Docetaxel for paclitaxel-resistant case.
Sponsors
Aichi Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histological proven esophageal cancer (excluding small cell carcinoma and neuroendocrine carcinoma) 2) Measurable lesions not required 3) Following previous treatment Intolerant or refractory to 5FU and cisplatin. Refractory to paclitaxel or docetaxel. 4) Age>20 or older 5) ECOG performance status 0-2 6) Adequate interval from previous treatments 7) Adequate organ function 8) Expected >8 weeks survival 9) Written informed consent from patient
Exclusion criteria
Exclusion criteria: Symptomatic brain metastasis Paralytic or mechanical bowel obstruction Confirmed or suspected infection Severe pulmonary disease (interstitial pneumonia, pulmonary fobrosis, severe emphysematous) Severe comorbidity (uncontrolable diabetes, heart failure with NYHA 3 or 4, renal failure, liver failure) Pregnant or possibly pregnant, and nursing women Sever neurologic disease Other conditions not suitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate, disease control rate, progression free survival, toxicity, QOL | — |
Countries
Japan
Contacts
Public ContactUra Takashi
Aichi Cancer Center Hospital Department of Clinical Oncology
Outcome results
None listed